Valproate Teratogenicity: A Moving Target

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Teratology

Background:

• Valproate, approved by the U.S. Food and Drug Administration (FDA) in the late 1970s, has been linked to severe adverse effects in offspring.
• Despite established risks of major congenital malformations and learning disabilities, its use during pregnancy has continued for over 40 years.
• Recent legal actions, including lawsuits and criminal indictments, underscore the ongoing concerns surrounding valproate's use in pregnant populations.

Purpose of the Study:

• To review the persistent use of valproate in pregnancy despite known teratogenic risks.
• To highlight the expanding indications for valproate beyond epilepsy treatment during pregnancy.
• To emphasize the lack of specific FDA Risk Evaluation and Mitigation Strategies for valproate and the implications for patient safety.

Main Methods:

• Review of historical data on valproate approval and teratogenicity.
• Analysis of recent prescribing trends for valproate in pregnant women.
• Examination of FDA regulatory actions concerning high-risk medications.

Main Results:

• Valproate use in pregnancy has persisted for decades, leading to significant risks for congenital malformations and developmental issues.
• Prescription of valproate during pregnancy has expanded beyond epilepsy to include bipolar depression and migraine treatment.
• Valproate is notably absent from the FDA's list of drugs with Risk Evaluation and Mitigation Strategies.

Conclusions:

• The continued use of valproate in pregnancy, despite well-documented teratogenic effects, represents a significant public health concern.
• The lack of specific FDA risk management strategies for valproate necessitates heightened vigilance from healthcare providers.
• Preventing adverse outcomes associated with valproate exposure in pregnancy relies on informed clinical practice and patient counseling.